A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Transcriptomic studies in clinical research are essential tools for deciphering the functional elements of the genome and unraveling underlying disease mechanisms. Various technologies have been developed to deduce and quantify the transcriptome including hybridization and sequencing-based approaches. Recently, high density exon microarrays have been successfully employed for detecting differentially expressed genes and alternative splicing events for biomarker discovery and disease diagnostics. The field of transcriptomics is currently being revolutionized by high throughput DNA sequencing methodologies to map, characterize, and quantify the transcriptome. METHODS: In an effort to understand the merits and limitations of each of these tools, we undertook a study of the transcriptome in sickle cell disease, a monogenic disease comparing the Affymetrix Human Exon 1.0 ST microarray (Exon array) and Illumina's deep sequencing technology (RNA-seq) on whole blood clinical specimens. RESULTS: Analysis indicated a strong concordance (R = 0.64) between Exon array and RNA-seq data at both gene level and exon level transcript expression. The magnitude of differential expression was found to be generally higher in RNA-seq than in the Exon microarrays. We also demonstrate for the first time the ability of RNA-seq technology to discover novel transcript variants and differential expression in previously unannotated genomic regions in sickle cell disease. In addition to detecting expression level changes, RNA-seq technology was also able to identify sequence variation in the expressed transcripts. CONCLUSIONS: Our findings suggest that microarrays remain useful and accurate for transcriptomic analysis of clinical samples with low input requirements, while RNA-seq technology complements and extends microarray measurements for novel discoveries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin
Tanno, T., Bhanu, N. V., Oneal, P. A., Goh, S.-H., Staker, P., Lee, Y. T., Moroney, J. W., Reed, C. H., Luban, N. L., Wang, R.-H., et al. (2007) · Nature Medicine · doi:10.1038/nm1629 · Cited by 854 · cited 1×
“Interestingly, GDF15 expression was upregulated, which also has been observed in thalassemia intermedia, and associated with repression of hepcidin, an important mediator of the inflammatory response on erythropoiesis [35].”
BackgroundHuman transcriptome array for high-throughput clinical studies
Xu, W., Seok, J., Mindrinos, M. N., Schweitzer, A. C., Jiang, H., Wilhelmy, J., Clark, T. A., Kapur, K., Xing, Y., Faham, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019753108 · Cited by 124
Research works printed but not linked: 35
- Melton SD, Genta RM, Souza RF: Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms. Nat Rev Gastroenterol Hepatol. 2010, 7 (11): 620-628. · DOI
- Rudan I: New technologies provide insights into genetic basis of psychiatric disorders and explain their co-morbidity. Psychiatr Danub. 2010, 22 (2): 190-192.
- Weitzel JN, Blazer KR, Macdonald DJ, Culver JO, Offit K: Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin. 2011, 61 (5): 327-359. · DOI · Paper page
- Yang X, Jiao R, Yang L, Wu LP, Li YR, Wang J: New-generation high-throughput technologies based 'omics' research strategy in human disease. Yi Chuan. 2011, 33 (8): 829-846.
- Offit K: Personalized medicine: new genomics, old lessons. Hum Genet. 2011, 130 (1): 3-14. · DOI · Paper page
- Lam CW, Lau KC, Tong SF: Microarrays for personalized genomic medicine. Adv Clin Chem. 2011, 52: 1-18. · DOI
- Abdueva D, Wing MR, Schaub B, Triche TJ: Experimental comparison and evaluation of the Affymetrix exon and U133Plus2 GeneChip arrays. PLoS One. 2007, 2 (9): e913. · doi:10.1371/journal.pone.0000913
- Bradford JR, Hey Y, Yates T, Li Y, Pepper SD, Miller CJ: A comparison of massively parallel nucleotide sequencing with oligonucleotide microarrays for global transcription profiling. BMC Genomics. 2010, 11: 282. · DOI · Paper page
- Liu JM, Camilli A: Discovery of bacterial sRNAs by high-throughput sequencing. Methods Mol Biol. 2011, 733: 63-79. · doi:10.1007/978-1-61779-089-8_5
- Cirulli ET, Singh A, Shianna KV, Ge D, Smith JP, Maia JM, Heinzen EL, Goedert JJ, Goldstein DB: Screening the human exome: a comparison of whole genome and whole transcriptome sequencing. Genome Biol. 2010, 11 (5): R57. · DOI · Paper page
- Tang F, Barbacioru C, Nordman E, Li B, Xu N, Bashkirov VI, Lao K, Surani MA: RNA-Seq analysis to capture the transcriptome landscape of a single cell. Nat Protoc. 2010, 5 (3): 516-535. · DOI · Paper page
- Nagalakshmi U, Waern K, Snyder M: RNA-Seq: a method for comprehensive transcriptome analysis. Curr Protoc Mol Biol. 2010, Chapter 4: 11-13. Unit 4 11
- Tariq MA, Kim HJ, Jejelowo O, Pourmand N: Whole-transcriptome RNAseq analysis from minute amount of total RNA. Nucleic Acids Res. 2011, 39 (18): e120. · DOI · Paper page
- Zhao J, Grant SF: Advances in whole genome sequencing technology. Curr Pharm Biotechnol. 2010, 12 (2): 293-305. · DOI
- Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y: RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008, 18 (9): 1509-1517. · DOI · Paper page
- Liu GE: Recent Applications of DNA Sequencing Technologies in Food, Nutrition and Agriculture. Recent Pat Food Nutr Agric. 2011, 3 (3): 187-195. · DOI
- Raghavachari N, Xu X, Munson PJ, Gladwin MT: Characterization of whole blood gene expression profiles as a sequel to globin mRNA reduction in patients with sickle cell disease. PLoS One. 2009, 4 (8): e6484. · DOI
- Trapnell C, Pachter L, Salzberg SL: TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009, 25 (9): 1105-1111. · DOI · Paper page
- Quinlan AR, Hall IM: BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010, 26 (6): 841-842. · DOI · Paper page
- Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B: Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008, 5 (7): 621-628. · DOI · Paper page
- Bieche I, Parfait B, Tozlu S, Lidereau R, Vidaud M: Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene. Carcinogenesis. 2001, 22 (9): 1521-1526. · DOI · Paper page
- Ma Q, Lu AY: Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011, 63 (2): 437-459. · DOI · Paper page
- Mardis ER: A decade's perspective on DNA sequencing technology. Nature. 2011, 470 (7333): 198-203. · DOI · Paper page
- Taylor BS, Ladanyi M: Clinical cancer genomics: how soon is now?. J Pathol. 2010, 223 (2): 318-326.
- Tommasi S, Danza K, Pilato B, De Summa S: Innovative technology for cancer risk analysis. Ann Oncol. 2011, 22 (Suppl 1): i37-43. · DOI
- Schweiger MR, Kerick M, Timmermann B, Isau M: The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations. Cancer Metastasis Rev. 2011, 30 (2): 199-210. · DOI
- Settle SH, Sulman EP: Tumor profiling: development of prognostic and predictive factors to guide brain tumor treatment. Curr Oncol Rep. 2010, 13 (1): 26-36. · DOI
- Morris CR: Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program. 2008, 177-185.
- Jison ML, Munson PJ, Barb JJ, Suffredini AF, Talwar S, Logun C, Raghavachari N, Beigel JH, Shelhamer JH, Danner RL, Gladwin MT: Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004, 104 (1): 270-280. · DOI · Paper page
- Steinberg MH, Brugnara C: Pathophysiological-based approaches to treatment of sickle cell disease. Annu Rev Med. 2003, 54: 89-112. · DOI
- Raghavachari N, Xu X, Harris A, Villagra J, Logun C, Barb J, Solomon MA, Suffredini AF, Danner RL, Kato G, et al: Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. Circulation. 2007, 115 (12): 1551-1562. · DOI
- Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT: Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol. 2009, 84 (9): 618-625. · DOI · Paper page
- Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C, Lambert N, Ouachee-Chardin M, Chedeville G, Tamary H, et al: Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003, 115 (4): 461-473. · DOI · Paper page
- Cotter PD, Willard HF, Gorski JL, Bishop DF: Assignment of human erythroid delta-aminolevulinate synthase (ALAS2) to a distal subregion of band Xp11.21 by PCR analysis of somatic cell hybrids containing X; autosome translocations. Genomics. 1992, 13 (1): 211-212. · DOI
- Cox TC, Bawden MJ, Martin A, May BK: Human erythroid 5-aminolevulinate synthase: promoter analysis and identification of an iron-responsive element in the mRNA. The EMBO journal. 1991, 10 (7): 1891-1902. · DOI · Paper page
Cited by
The human transcriptome across tissues and individuals
Melé, M., Ferreira, P. G., Reverter, F., DeLuca, D. S., Monlong, J., Sammeth, M., Young, T. R., Goldmann, J. M., Pervouchine, D. D., Sullivan, T. J., et al. (2015) · Science · doi:10.1126/science.aaa0355 · Cited by 1,304
SEQC/MAQC-III Consortium (2014) · Nature Biotechnology · doi:10.1038/nbt.2957 · Cited by 983
Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer
Du, Z., Fei, T., Verhaak, R. G. W., Su, Z., Zhang, Y., Brown, M., Chen, Y., & Liu, X. S. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2591 · Cited by 539
Wang, C., Gong, B., Bushel, P. R., Thierry-Mieg, J., Thierry-Mieg, D., Xu, J., Fang, H., Hong, H., Shen, J., Su, Z., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3001 · Cited by 512
Self-citationReproducibility of high-throughput mRNA and small RNA sequencing across laboratories
The GEUVADIS Consortium, 't Hoen, P. A. C., Friedländer, M. R., Almlöf, J., Sammeth, M., Pulyakhina, I., Anvar, S. Y., Laros, J. F. J., Buermans, H. P. J., Karlberg, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2702 · Cited by 250
Metadata
- Authors
- Raghavachari, N., Barb, J., Yang, Y., Liu, P., Woodhouse, K., Levy, D., O‘Donnell, C. J., Munson, P. J., & Kato, G. J.
- Venue
- BMC Medical Genomics
- Published
- 2012-06-29
- Volume
- 5
- Issue
- 1
- Pages
- 28-28
- ISSN
- 1755-8794 (ISSN-L)
- OpenAlex
- W1968550393
- Cited by
- 90
- References
- 3
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease. https://app.cochat.ai/papers/10.1186/1755-8794-5-28
- The paper
- Raghavachari, N., Barb, J., Yang, Y., Liu, P., Woodhouse, K., Levy, D., O‘Donnell, C. J., Munson, P. J., & Kato, G. J. (2012). A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease. BMC Medical Genomics. https://doi.org/10.1186/1755-8794-5-28
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.